捷順科技(002609.SZ):中標1.088億元海口美蘭城市級智慧停車投建運營一體化項目
格隆匯11月26日丨捷順科技(002609.SZ)宣佈,2020年11月26日,公司收到招標人海口市美蘭區旅遊投資發展有限公司、招標代理機構海南才子招標代理有限公司發出的《中標通知書》,確定公司為“城市智慧停車美蘭試點項目引進社會資本方採購項目”的中標單位,公司作為社會資本方、聯合運營方參與海口市美蘭區城市級智慧停車投建運營一體化項目,中標總金額為人民幣1.088億元,項目運營期5年。
公司表示,此次項目中標,將進一步完善公司城市停車業務的市場佈局,提升公司城市停車業務的市場規模和綜合競爭力。如項目順利實施交付對公司未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.